^
Association details:
| Biomarker: | ATM deletion |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | berzosertib (M6620) (ATR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
Published date:
06/22/2020
Excerpt:
Forty patients were enrolled; 17 received M6620 monotherapy, which was safe and well tolerated...A patient with metastatic colorectal cancer harboring molecular aberrations, including ATM loss and an ARID1A mutation, achieved RECISTv1.1 complete response and maintained this response, with a progression-free survival of 29 months at last assessment.
DOI:
10.1200/JCO.19.02404
Trial ID:
Source:
Title:
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
Published date:
06/22/2020
Excerpt:
...this report is the first of an ATR inhibitor as monotherapy and combined with carboplatin. M6620 was well tolerated, with target engagement and preliminary antitumor responses observed.
Secondary therapy:
carboplatin
DOI:
10.1200/JCO.19.02404
Trial ID:
